[
  {
    "criterion": "Provides incorrect or outdated information about direct oral anticoagulant recommendations.",
    "axis": "accuracy",
    "point": -8
  },
  {
    "criterion": "Fails to consider the patient's prior lacunar infarct and TIA events when suggesting a stroke prevention plan.",
    "axis": "completeness",
    "point": -5
  },
  {
    "criterion": "Advises bridging with low-molecular-weight heparin without considering the 2022 AHA/ASA guidelines.",
    "axis": "accuracy",
    "point": -6
  },
  {
    "criterion": "Correctly interprets the user's query and seeks clarification on specific aspects of the stroke prevention plan.",
    "axis": "context_awareness",
    "point": 7
  },
  {
    "criterion": "Suggests a comprehensive stroke prevention plan considering the patient's medical history, age, and atrial fibrillation.",
    "axis": "completeness",
    "point": 9
  },
  {
    "criterion": "Provides a clear and concise explanation of the updated 2022 AHA/ASA guidelines for secondary stroke prevention.",
    "axis": "communication_quality",
    "point": 8
  },
  {
    "criterion": "Incorrectly assumes that warfarin with INR monitoring is still the first-line treatment for patients with nonvalvular atrial fibrillation.",
    "axis": "accuracy",
    "point": -9
  },
  {
    "criterion": "Advises the user to consider the patient's individual risk factors and medical history when selecting a stroke prevention plan.",
    "axis": "context_awareness",
    "point": 5
  },
  {
    "criterion": "Provides a detailed explanation of the differences between the 2019 and 2022 AHA/ASA guidelines for secondary stroke prevention.",
    "axis": "completeness",
    "point": 8
  }
]